What SAB Biotherapeutics, Inc. does.

We are a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Our programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials in indications with significant unmet medical needs. We are focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to potentially change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients.

Using advanced genetic engineering and antibody science, we developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. We believe it is the only technology capable of producing disease-targeted, hIgG in large quantities without human plasma donors.

Revenue and profit, by fiscal year.

More on SABS.

• SAB Biotherapeutics, Inc. summary
• SAB Biotherapeutics, Inc. financial statements
• SAB Biotherapeutics, Inc. key metrics
• SAB Biotherapeutics, Inc. health scores and style box
• SAB Biotherapeutics, Inc. earnings
• SAB Biotherapeutics, Inc. dividends
• SAB Biotherapeutics, Inc. valuation
• SAB Biotherapeutics, Inc. ownership and insiders
• SAB Biotherapeutics, Inc. peers

Figures from SAB Biotherapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.